Pharma News

Keep updating your pharma knowledge
21 Jul 2020

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial published in The Lancet Journal

ChAdOx1 Covid-19 vaccine in clinical study

The Oxford shot is one of the front runners in the vaccine race and is already undergoing a combined clinical Phase II/III trials in the UK, Brazil and South Africa. In a significant development, the Covid-19 vaccine jointly developed by British-Swedish company AstraZeneca and the University of Oxford has been found to be safe and induced an immune response in early-stage clinical trials.

The AZD1222 vaccine, based on a chimpanzee adenovirus called ChAdOx1, elicited antibody and T-cell immune responses, according to results published in The Lancet medical journal on Monday.

ChAdOx1 nCoV-19 Clinical Study _ 20th July _ The Lancet

What is Oxford’s ChAdOx1 Covid-19 vaccine?

Oxford’s AZD1222 vaccine is made from a genetically engineered virus that causes the common cold in chimpanzees. However, the virus has been modified so that it doesn’t cause infection in people and also to mimic the coronavirus.

Scientists did this by transferring the genetic instructions of the coronavirus’ “spike protein” – the crucial tool it uses to invade human cells – to the vaccine. This was done so that the vaccine resembles the coronavirus and the immune system can learn how to attack it.

KPE – C- 022 KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!